Edition:
United Kingdom

Leap Therapeutics Inc (LPTX.OQ)

LPTX.OQ on NASDAQ Stock Exchange Global Market

3.80USD
16 Nov 2018
Change (% chg)

$0.30 (+8.57%)
Prev Close
$3.50
Open
$3.46
Day's High
$3.81
Day's Low
$3.46
Volume
5,415
Avg. Vol
11,387
52-wk High
$10.25
52-wk Low
$3.46

Latest Key Developments (Source: Significant Developments)

Leap Therapeutics Qtrly Loss Per Share $0.55
Friday, 9 Nov 2018 

Nov 9 (Reuters) - Leap Therapeutics Inc ::LEAP THERAPEUTICS REPORTS THIRD QUARTER 2018 BUSINESS UPDATE AND FINANCIAL RESULTS.LEAP THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.55.LEAP THERAPEUTICS INC - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $23.2 MILLION AT SEPTEMBER 30, 2018.LEAP THERAPEUTICS INC - ANTICIPATE THAT CURRENT CASH RESOURCES WILL EXTEND UNTIL LATE IN Q3 OF 2019.  Full Article

Leap Therapeutics Qtrly Net Loss Per Share $0.50
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Leap Therapeutics Inc ::LEAP THERAPEUTICS REPORTS SECOND QUARTER 2018 BUSINESS UPDATE AND FINANCIAL RESULTS.LEAP THERAPEUTICS INC - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $30.5 MILLION AT JUNE 30, 2018..LEAP THERAPEUTICS SAYS CURRENT CASH POSITION SUFFICIENT TO FUND OPERATING. EXPENSES INTO Q4 2019.LEAP THERAPEUTICS INC - QTRLY NET LOSS PER SHARE $0.50.  Full Article

Leap Therapeutics Announces Collaboration With Merck KGaA, Darmstadt, Germany, And Pfizer
Monday, 23 Jul 2018 

July 23 (Reuters) - Leap Therapeutics Inc ::LEAP THERAPEUTICS ANNOUNCES COLLABORATION WITH MERCK KGAA, DARMSTADT, GERMANY, AND PFIZER TO EVALUATE COMBINATION OF TRX518, AVELUMAB, AND CHEMOTHERAPY IN ADVANCED SOLID TUMORS.LEAP THERAPEUTICS INC - LEAP WILL BE CONDUCTING A PHASE I/II CLINICAL TRIAL IN ADVANCED SOLID TUMORS.LEAP THERAPEUTICS INC - STUDY IS EXPECTED TO BEGIN ENROLLING PATIENTS IN Q1 OF 2019.  Full Article

Leap Therapeutics Reports Qtrly Loss Per Share Of $0.85
Friday, 11 May 2018 

May 11 (Reuters) - Leap Therapeutics Inc ::LEAP THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.QTRLY LOSS PER SHARE $0.85.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $35.4 MILLION AT MARCH 31, 2018.  Full Article

Leap Therapeutics Files For Resale Of Up To 3.73 Mln Shares Of Co's Common Stock By Selling Stockholders
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Leap Therapeutics Inc ::LEAP THERAPEUTICS INC FILES FOR RESALE OF UP TO 3.73 MILLION SHARES OF CO'S COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING.  Full Article

Eli Lilly And Co reports 17.5 pct passive stake in Leap Therapeutics ‍​as of Nov 14
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - Eli Lilly And Co :Eli Lilly And Co reports 17.5 percent passive stake in Leap Therapeutics Inc‍​ ‍​as of November 14 - SEC Filing.  Full Article

Leap Therapeutics announces $18 million private placement offering
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Leap Therapeutics Inc ::Announces $18 million private placement offering.Upon closing of transaction, leap will sell 2.96 million shares of unregistered common stock​.Signed voting agreement with HealthCare Ventures to vote shares in favor of approval proposed at stockholders​ special meeting.To sell shares in private placement with select institutional investors, strategic partners, including HealthCare Ventures, Eli Lilly.  Full Article

Leap Therapeutics qtrly loss per share $0.73
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Leap Therapeutics Inc -:Leap Therapeutics reports third quarter 2017 financial results and announces first patient dosed with DKN-01 and Keytruda® (pembrolizumab) in esophagogastric cancer trial.Leap Therapeutics Inc - ‍cash, cash equivalents and marketable securities totaled $14.2 million at September 30, 2017​.Leap Therapeutics Inc - ‍net loss was $6.8 million for Q3 of 2017, compared to $7.3 million for same period in 2016​.Leap therapeutics inc - qtrly loss per share $0.73.  Full Article